Suppr超能文献

膀胱癌治疗选择的膀胱内治疗与手术比较(CISTO)研究:在一项大型、务实、以患者为中心的试验中关于管理和患者入组的经验教训。

The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial.

作者信息

Nathan Krupa K, Follmer Kristin M, Nash Michael G, Wolff Erika M, Lee Jenney R, Mecham Solange, Yano Marielle, Kim Sung Min, Comstock Bryan A, Gore John L, Smith Angela B

机构信息

Department of Urology, University of North Carolina, Chapel Hill, North Carolina, USA.

Department of Urology, University of Washington, Seattle, Washington, USA.

出版信息

Cancer. 2025 Jan 1;131(1):e35600. doi: 10.1002/cncr.35600. Epub 2024 Oct 14.

Abstract

BACKGROUND

The growth of patient and public involvement in clinical research highlights the paucity of literature on operational practices that ensure the success of large, patient-centered outcomes trials. The authors' objective was to identify tools launched by the Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study team to determine their effectiveness in maximizing patient enrollment in this observational, pragmatic trial.

METHODS

The primary outcomes for this study were patient screening and enrollment across 36 CISTO study sites. The operational strategies included CISTOquestion email correspondence and All Sites Meetings, specifically poll performance data from meetings, and a nonanonymized feedback survey about the CISTO study's management practices. Effectiveness was measured using correlation analysis with patient cohort data, including screenings, enrollments, post-hoc exclusions, and the post-hoc exclusion rate.

RESULTS

Average screenings and enrollment rose after the implementation of CISTOquestion in April 2021, with the average number of screenings rising from 7.42 to 26.8 patients per month and enrollment rising from 3.76 to 16 patients per month. Use of CISTOquestion was correlated strongly with increased patient screenings and enrollment across all study sites. Eighty-three percent of sites with above-average post-hoc exclusion rates (≥0.092) sent below the average number of CISTOquestion inquiries. Poll performance and survey data revealed that all survey respondents who used CISTOquestion found that it was a valuable and accessible resource.

CONCLUSIONS

Of the several operational tools implemented within the CISTO study that aimed to improve patient enrollment, CISTOquestion, a centralized email for addressing eligibility questions, was most beneficial to overall patient accrual.

摘要

背景

患者和公众参与临床研究的情况日益增多,这凸显了关于确保大型以患者为中心的结局试验取得成功的操作实践的文献匮乏。作者的目标是确定膀胱癌膀胱内治疗与手术比较作为治疗选择(CISTO)研究团队推出的工具,以确定其在这项观察性务实试验中最大限度提高患者入组率方面的有效性。

方法

本研究的主要结局是36个CISTO研究地点的患者筛查和入组情况。操作策略包括CISTOquestion电子邮件通信和所有站点会议,具体是汇总会议的投票绩效数据,以及关于CISTO研究管理实践的非匿名反馈调查。使用与患者队列数据的相关分析来衡量有效性,这些数据包括筛查、入组、事后排除和事后排除率。

结果

2021年4月实施CISTOquestion后,平均筛查和入组人数有所增加,每月平均筛查人数从7.42人增至26.8人,入组人数从3.76人增至16人。在所有研究地点,CISTOquestion的使用与患者筛查和入组人数的增加密切相关。事后排除率高于平均水平(≥0.092)的站点中,83%发送的CISTOquestion询问数量低于平均水平。投票绩效和调查数据显示,所有使用CISTOquestion的调查受访者都认为它是一种有价值且易于获取的资源。

结论

在CISTO研究中实施的旨在提高患者入组率的几种操作工具中,CISTOquestion(一个用于解决资格问题的集中式电子邮件)对总体患者招募最为有益。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验